Insuman Comb 25 (Insulin Human)

Insulin human binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake and storage while suppressing hepatic glucose production. This combined action lowers circulating glucose and restores normal metabolic balance.

The dose of Insuman Comb 25 is individualized. A qualified prescriber determines the amount based on the patient’s blood‑glucose readings, body weight, diet, activity level and response to therapy. Dosage adjustments are made during follow‑up visits to maintain optimal control.

Insulin is the preferred glucose‑lowering agent during pregnancy because it does not cross the placenta. Insuman Comb 25 may be used under medical supervision in pregnant or lactating women, but the prescriber should weigh benefits against any potential risks.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Insuman Comb 25 contains human insulin, which has a slower onset and longer duration than rapid‑acting analogues such as insulin lispro or aspart. It is often used when a more gradual insulin profile is desired, whereas rapid‑acting analogues are preferred for mealtime spikes due to their quicker action.

Store Insuman Comb 25 refrigerated between 2 °C and 8 °C. Protect the vial from light, do not freeze, and avoid shaking. Once in use, it may be kept at controlled room temperature (up to 25 °C) for a limited period as indicated on the label.

Insuman Comb 25 is given by subcutaneous injection, typically into the abdomen, thigh or upper arm. Use a sterile needle or an appropriate insulin pen, rotate injection sites to reduce lipodystrophy, and follow the prescriber’s instructions for timing relative to meals.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and systemic allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs and have emergency glucose sources available.

Insuman Comb 25 should not be used by individuals with a known hypersensitivity to human insulin or any excipients in the formulation. It is also contraindicated in patients with severe hypoglycaemia unawareness who cannot reliably monitor or respond to low glucose episodes.